FDA approves Sanofi's monoclonal antibody treatment for CAD

[cafead]

via The US Food and Drug Administration (FDA) has approved Enjaymo (sutimlimab-jome) to decrease the need for red blood cell transfusion due to hemolysis in adults with cold agglutinin disease (CAD).

article source